Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# KSQ Therapeutics

## Sitemaps

- [XML Sitemap](https://ksqtx.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [Home](https://ksqtx.com/) - Tackling the toughest challenges in medicine with the aspiration to cure human diseases.
- [Pipeline](https://ksqtx.com/pipeline/) - [et_pb_section fb_built=”1″ admin_label=”Banner Section” module_id=”platform” module_class=”innerBanner” _builder_version=”4.24.2″ _module_preset=”default” background_enable_image=”off” background_video_mp4=”https://ksqtx.com/wp-content/uploads/2024/06/DJI_20240201_103510_678_video.mp4″ height=”500px” overflow-x=”hidden” overflow-y=”hidden” custom_padding=”199px||199px||true|false” bottom_divider_height=”500px” da_popup_slug=”platform” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row custom_padding_last_edited=”on|tablet” _builder_version=”4.24.2″ _module_preset=”default” width=”100%” width_tablet=”100%” width_phone=”100%” width_last_edited=”on|desktop” max_width=”100%” overflow-x=”hidden” overflow-y=”hidden” custom_margin=”|60px||60px|false|true” custom_margin_tablet=”|20px||20px|false|true” custom_margin_phone=”|20px||20px|false|true” custom_margin_last_edited=”on|tablet” custom_padding_tablet=”0px||0px||false|false” custom_padding_phone=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Vertical Line” _builder_version=”4.24.2″ _module_preset=”default” positioning=”absolute” width=”100%” height=”100%”
- [About](https://ksqtx.com/about/) - [et_pb_section fb_built=”1″ admin_label=”Banner Section” module_class=”innerBanner” _builder_version=”4.24.2″ _module_preset=”default” background_image=”https://ksqtx.com/wp-content/uploads/2024/06/81_KSQ_2024.02.01_Genevieve-de-Manio-Photography-scaled.jpg” position_origin_f=”top_center” height=”500px” overflow-x=”hidden” overflow-y=”hidden” custom_padding=”200px||200px||true|false” scroll_vertical_motion=”0|50|50|100|0|0|4″ da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row custom_padding_last_edited=”on|tablet” _builder_version=”4.24.2″ _module_preset=”default” width=”100%” max_width=”100%” overflow-x=”hidden” overflow-y=”hidden” custom_margin=”|60px||60px|false|true” custom_margin_tablet=”|20px||20px|false|true” custom_margin_phone=”|20px||20px|false|true” custom_margin_last_edited=”on|tablet” custom_padding_tablet=”0px||0px||false|false” custom_padding_phone=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Vertical Line” _builder_version=”4.24.2″ _module_preset=”default” positioning=”absolute” width=”100%” height=”100%” animation_style=”slide” animation_direction=”top” border_width_left=”6px” border_color_left=”#FFFFFF” global_colors_info=”{}”][/et_pb_text][et_pb_cta
- [Partners](https://ksqtx.com/partners/) - [et_pb_section fb_built=”1″ admin_label=”Banner Section” module_class=”orangeShape innerBanner” _builder_version=”4.24.2″ _module_preset=”default” background_image=”https://ksqtx.com/wp-content/uploads/2024/06/iStock-1177326469-web.jpg” background_enable_video_mp4=”off” height=”500px” overflow-x=”hidden” overflow-y=”hidden” custom_padding=”199px||199px||true|false” bottom_divider_height=”500px” da_popup_slug=”platform” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row custom_padding_last_edited=”on|tablet” module_class=”our-pipeline” _builder_version=”4.24.2″ _module_preset=”default” width=”100%” max_width=”100%” overflow-x=”hidden” overflow-y=”hidden” custom_margin=”|60px||60px|false|true” custom_margin_tablet=”|20px||20px|false|true” custom_margin_phone=”|20px||20px|false|true” custom_margin_last_edited=”on|tablet” custom_padding_tablet=”0px||0px||false|false” custom_padding_phone=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Vertical Line” _builder_version=”4.24.2″ _module_preset=”default” positioning=”absolute” width=”100%” height=”100%” animation_style=”slide” animation_direction=”top”
- [Platform](https://ksqtx.com/platform/) - [et_pb_section fb_built=”1″ admin_label=”Banner Section” module_class=”lightBlueShape innerBanner” _builder_version=”4.24.2″ _module_preset=”default” background_enable_image=”off” background_video_mp4=”https://ksqtx.com/wp-content/uploads/2024/06/iStock-537852616-edit.mp4″ height=”500px” overflow-x=”hidden” overflow-y=”hidden” custom_padding=”180px||180px||true|false” bottom_divider_height=”500px” da_popup_slug=”platform” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row custom_padding_last_edited=”on|tablet” _builder_version=”4.24.2″ _module_preset=”default” width=”100%” max_width=”100%” overflow-x=”hidden” overflow-y=”hidden” custom_margin=”|60px||60px|false|true” custom_margin_tablet=”|20px||20px|false|true” custom_margin_phone=”|20px||20px|false|true” custom_margin_last_edited=”on|tablet” custom_padding_tablet=”0px||0px||false|false” custom_padding_phone=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Vertical Line” _builder_version=”4.24.2″ _module_preset=”default” positioning=”absolute” width=”100%” height=”100%” animation_style=”slide” animation_direction=”top” border_width_left=”6px”
- [News](https://ksqtx.com/news/) - [et_pb_section fb_built=”1″ admin_label=”Banner Section” module_class=”orangeShape innerBanner” _builder_version=”4.24.2″ _module_preset=”default” background_image=”https://ksqtx.com/wp-content/uploads/2024/06/205_KSQ_2024.02.01_Genevieve-de-Manio-Photography-scaled-e1719331769716.jpg” background_position=”top_center” background_enable_video_mp4=”off” height=”500px” overflow-x=”hidden” overflow-y=”hidden” custom_padding=”199px||199px||true|false” bottom_divider_height=”500px” background_last_edited=”on|phone” background_position_phone=”top_right” background_horizontal_offset_phone=”6%” da_popup_slug=”platform” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row custom_padding_last_edited=”on|phone” _builder_version=”4.24.2″ _module_preset=”default” width=”100%” width_tablet=”100%” width_phone=”100%” width_last_edited=”on|desktop” max_width=”100%” overflow-x=”hidden” overflow-y=”hidden” custom_margin=”|60px||60px|false|true” custom_margin_tablet=”|20px||20px|false|true” custom_margin_phone=”|20px||20px|false|true” custom_margin_last_edited=”on|desktop” custom_padding_tablet=”0px||0px||true|false” custom_padding_phone=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Vertical Line” _builder_version=”4.24.2″
- [Careers](https://ksqtx.com/careers/) - [et_pb_section fb_built=”1″ admin_label=”Banner Section” module_id=”platform” module_class=”innerBanner” _builder_version=”4.24.2″ _module_preset=”default” background_enable_image=”off” background_video_mp4=”https://ksqtx.com/wp-content/uploads/2024/06/KSQoffice.mp4″ height=”500px” overflow-x=”hidden” overflow-y=”hidden” custom_padding=”199px||199px||true|false” bottom_divider_height=”500px” da_popup_slug=”platform” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row custom_padding_last_edited=”on|tablet” _builder_version=”4.24.2″ _module_preset=”default” width=”100%” max_width=”100%” overflow-x=”hidden” overflow-y=”hidden” custom_margin=”|60px||60px|false|true” custom_margin_tablet=”|20px||20px|false|true” custom_margin_phone=”|20px||20px|false|true” custom_margin_last_edited=”on|tablet” custom_padding_tablet=”0px||0px||false|false” custom_padding_phone=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Vertical Line” _builder_version=”4.24.2″ _module_preset=”default” positioning=”absolute” width=”100%” height=”100%” animation_style=”slide” animation_direction=”top” border_width_left=”6px”
- [Expanded Access Policy](https://ksqtx.com/eap/) - [et_pb_section fb_built=”1″ admin_label=”Section” module_class=”innerBanner” _builder_version=”4.24.2″ _module_preset=”default” background_color=”RGBA(255,255,255,0)” background_image=”https://ksqtx.com/wp-content/uploads/2024/06/cell-crop-orange-scaled.jpg” background_enable_video_mp4=”off” height=”500px” custom_padding=”199px||199px||true|false” bottom_divider_height=”500px” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row custom_padding_last_edited=”on|tablet” _builder_version=”4.24.2″ _module_preset=”default” width=”100%” max_width=”100%” custom_padding=”|60px||60px|false|true” custom_padding_tablet=”0px|20px|0px|20px|false|true” custom_padding_phone=”|20px||20px|false|true” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_column type=”4_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_cta _builder_version=”4.24.2″ _module_preset=”default” header_font=”Nunito Sans|700||on|||||” header_text_color=”#FFFFFF” header_font_size=”20px” header_letter_spacing=”1px” header_line_height=”20px” body_font=”Nunito Sans|300||on|||||” body_text_color=”#FFFFFF” body_font_size=”40px” body_letter_spacing=”0.5px” body_line_height=”44px” use_background_color=”off” text_orientation=”left” max_width=”500px”

## Pipelines

- [KSQ-4279](https://ksqtx.com/pipelines/ksq-4279/) - KSQ-4279 is a first-in-class, potent, and selective small-molecule inhibitor of USP1, a protein that regulates DNA damage response (DDR). In July 2023, we entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279 (RO7623066/RG6614). KSQ-4279 (RO7623066/RG6614) was studied in a Phase 1 clinical trial in patients with a variety of advanced solid tumors
- [KSQ-004EX](https://ksqtx.com/pipelines/ksq-004ex/) - KSQ-004EX, a dual-edit eTIL investigational therapy in which both the Regnase-1 and SOCS1 genes are inactivated by CRISPR/Cas9 gene editing, is also manufactured using our ExPRESS process. Using our in vivo CRISPR2® screening approach, we identified Regnase-1 and SOCS1 as the genome’s top dual-edit combination driving best-in-biology anti-tumor potential. The U.S. Food and Drug Administration (FDA)
- [KSQ-001EX](https://ksqtx.com/pipelines/ksq-001ex/) - KSQ-001EX is an investigational eTIL therapy manufactured using our ExPRESS™ process in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. KSQ’s Immune CRISPRomics® platform identified SOCS1 as a top target, constraining TIL anti-tumor function, engraftment, and persistence. The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase 1/2 clinical study of KSQ-001EX.

## Platforms

- [USP1](https://ksqtx.com/platforms/usp1/) - USP1 was identified using our Targeted Oncology CRISPRomics platform due to its profile as selectively essential in certain biomarker-enabled cancer cell models and its role in DNA damage repair processes (DDR). USP1 is a member of the ubiquitin-specific processing (UBP) family of proteases with a role in DDR distinct from other mechanisms currently being evaluated in
- [Regnase-1](https://ksqtx.com/platforms/regnase-1/) - Regnase-1 is an endonuclease that regulates immune responses by degrading the messenger RNA (mRNA) of pro-inflammatory proteins. Using our in vivo CRISPR2® dual gene-editing screening approach, we identified Regnase-1 and SOCS1 as the genome’s top dual-edit combination in T cells, synergizing to drive best-in-biology activity in mouse cancer models that are refractory to all other therapies.
- [SOCS1](https://ksqtx.com/platforms/socs1/) - SOCS1 stands for: Suppressor Of Cytokine Signaling 1. SOCS1 is a negative regulator of T cell signaling by cytokines, the small proteins critical in controlling the growth and activity of immune cells responding to pathogens and cancer. We identified SOCS1 as a top target using our Immune CRISPRomics platform. Editing SOCS1 in TIL using CRISPR/Cas9

## Press Releases

- [KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy](https://ksqtx.com/press-releases/ksq-therapeutics-announces-first-patient-dosed-in-phase-1-2-study-for-ksq-004ex-a-crispr-cas9-engineered-tumor-infiltrating-lymphocyte-etil-therapy/) - Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumors Lexington, Mass., April 9, 2025 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-004EX, a novel CRISPR-engineered Tumor Infiltrating
- [KSQ Therapeutics Appoints Kristen Hege, M.D., to its Board of Directors](https://ksqtx.com/press-releases/ksq-therapeutics-appoints-kristen-hege-m-d-to-its-board-of-directors/) - Lexington, Mass., March 5, 2025 - KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, including engineered tumor-infiltrating lymphocyte (eTIL®) programs, today announced the appointment of Kristen Hege, M.D., to the company’s Board of Directors. Dr. Hege brings to KSQ’s board more than 20 years of leadership experience in oncology and
- [KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors](https://ksqtx.com/press-releases/ksq-therapeutics-appoints-john-lepore-m-d-to-its-board-of-directors/) - Lexington, Mass., October 22, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of John Lepore, M.D., to the company’s board of directors. Dr. Lepore brings over 20 years of leadership experience in R&D and drug discovery to KSQ’s board. “As we continue advancing
- [KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer](https://ksqtx.com/press-releases/ksq-therapeutics-appoints-anna-truppel-hartmann-m-d-as-chief-medical-officer/) - Lexington, Mass., October 8, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of Anna Truppel-Hartmann, M.D., as Chief Medical Officer. Dr. Truppel-Hartmann brings an accomplished track record in clinical development, medical affairs, patient engagement, and talent development. She will play a crucial role
- [KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy](https://ksqtx.com/press-releases/ksq-therapeutics-announces-fda-clearance-of-ind-application-for-ksq-004ex-a-crispr-cas9-engineered-tumor-infiltrating-lymphocyte-etil-therapy/) - Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumors Lexington, Mass., September 24, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) and the Cell Therapy Manufacturing
- [KSQ Therapeutics Emerges with $76 Million in Financing to Pioneer High-Confidence Drug Development](https://ksqtx.com/press-releases/ksq-therapeutics-emerges-with-76-million-in-financing-to-pioneer-high-confidence-drug-development/) - – World class executive team led by CEO David Meeker and CSO Frank Stegmeier – – Proprietary CRISPRomics™ Drug Discovery Engine Pinpoints the Best Therapeutic Nodes of Diseases; Product Insights Being Translated into Drug Candidates – Cambridge, Mass., October 2, 2017 – KSQ Therapeutics emerged today with $76 million in financing and a world-class executive
- [KSQ Therapeutics Appoints Richard Moscicki, MD, to Board of Directors](https://ksqtx.com/press-releases/ksq-therapeutics-appoints-richard-moscicki-md-to-board-of-directors/) - – Industry Leader Brings Expertise in Medical, Clinical and Regulatory Affairs in Drug Development – Cambridge, Mass., September 25, 2018 – KSQ Therapeutics today announced the appointment of Richard A. Moscicki, MD, to the company’s Board of Directors. Dr. Moscicki brings more than 25 years of leadership experience in translational medicine, clinical development, regulatory affairs
- [KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD 1 Resistant Solid Tumors](https://ksqtx.com/press-releases/ksq-therapeutics-secures-80-million-financing-and-advances-broad-pipeline-of-cancer-therapies-including-its-first-adoptive-t-cell-therapy-program-for-pd-1-resistant-solid-tumors/) - – Company’s Pipeline Spans Three Oncology Drug Categories: Adoptive T‑Cell Therapies, Immuno-Oncology Monotherapies and Targeted Therapies – – Proprietary CRISPRomics™ Discovery Engine Has Yielded 12 Oncology Drug Discovery Programs in 12 Months – CAMBRIDGE, Mass. – September 28, 2018 – KSQ Therapeutics announced today that the company has secured an $80 million Series C financing
- [CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology](https://ksqtx.com/press-releases/crispr-therapeutics-and-ksq-therapeutics-announce-license-agreement-to-advance-companies-respective-cell-therapy-programs-in-oncology/) - – CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs – – KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous cell therapies, including its existing eTILTM cell franchise – ZUG, Switzerland and CAMBRIDGE, Mass., October 15, 2019 – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical
- [KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine](https://ksqtx.com/press-releases/ksq-therapeutics-to-present-first-data-from-its-proprietary-crispromics-discovery-engine/) - – Posters at AACR-NCI-EORTC and SITC illustrate genome-wide, in vivo T-cell approach to identify and validate novel therapeutic immuno-oncology targets – CAMBRIDGE, Mass., October 28, 2019 – KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful discovery engine to achieve higher probabilities of success in drug development, today announced two upcoming
- [SITC Poster Presentation: "An Immune-CRISPRomics platform enabling genome-scale and pair-wise combination in vivo T-cell function screens enables comprehensive identification of novel therapeutic targets"](https://ksqtx.com/press-releases/sitc-poster-presentation-an-immune-crispromics-platform-enabling-genome-scale-and-pair-wise-combination-in-vivo-t-cell-function-screens-enables-comprehensive-identification-of-novel-therapeutic-tar/) - Click to download PDF file.
- [KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs](https://ksqtx.com/press-releases/ksq-therapeutics-to-present-at-the-piper-jaffray-31st-annual-healthcare-conference-and-provide-updates-on-immuno-oncology-and-cell-therapy-programs/) - Lead program declared as small molecule inhibitor of novel target in DDR pathway for the treatment of ovarian and breast cancers CAMBRIDGE, Mass., December 3, 2019 – KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that KSQ CEO David Meeker, M.D.,
- [MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs](https://ksqtx.com/press-releases/maxcyte-and-ksq-therapeutics-announce-development-and-commercialization-agreement-to-enable-the-advancement-of-ksqs-adoptive-cell-therapy-programs/) - Gaithersburg, MD and Cambridge, MA – December 4, 2019: MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development and commercialization agreement. Under the
- [KSQ Therapeutics Announces Discovery of Gene Targets with Potential Activity Superior to PD-1 for Development of Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapies for Solid Tumors](https://ksqtx.com/press-releases/ksq-therapeutics-announces-discovery-of-gene-targets-with-potential-activity-superior-to-pd-1-for-development-of-engineered-tumor-infiltrating-lymphocyte-etil-therapies-for-solid-tumors/) - Data demonstrate potential to increase efficacy of TIL adoptive cell therapy in preclinical models CAMBRIDGE, Mass., February 9, 2020 – KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the identification and validation of a
- [ASGCT Poster Presentation: "Systematic identification of potent guide RNAs with minimal off-target activity for the CRISPR/Cas9 engineering of KSQ-001, and engineered Tumor Infiltrating Lymphocyte (eTIL™)"](https://ksqtx.com/press-releases/asgct-poster-presentation-systematic-identification-of-potent-guide-rnas-with-minimal-off-target-activity-for-the-crispr-cas9-engineering-of-ksq-001-and-engineered-tumor-infiltrating-lymphocyte-e/) - Click to download PDF file.
- [AACR Poster Presentation: "KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapy for Solid Tumors](https://ksqtx.com/press-releases/aacr-poster-presentation-ksq-001-a-crispr-cas9-engineered-tumor-infiltrating-lymphocyte-etil-therapy-for-solid-tumors/) - Click to download PDF file.
- [KSQ Therapeutics to Present New Data from its USP1 Inhibitor Program at Upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics](https://ksqtx.com/press-releases/ksq-therapeutics-to-present-new-data-from-its-usp1-inhibitor-program-at-upcoming-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics/) - CAMBRIDGE, Mass., Sept. 24, 2020– KSQ® Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, announced it will present new data from its USP1 inhibitor program at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA
- [KSQ® Therapeutics Presents First Preclinical Data for KSQ-4279, a Novel USP1 Inhibitor, for the Treatment of BRCA-Deficient Cancers](https://ksqtx.com/press-releases/ksq-therapeutics-presents-first-preclinical-data-for-ksq-4279-a-novel-usp1-inhibitor-for-the-treatment-of-brca-deficient-cancers/) - 2020 ENA Plenary Slide Deck: “USP1 inhibitors show robust combination activity and a distinct resistance profile from PARP inhibitors” 2020 ENA Poster: “Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers” Data demonstrate robust single agent, combination activity and distinct resistance profile from PARP inhibitors CAMBRIDGE, Mass., October 24, 2020
- [KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies](https://ksqtx.com/press-releases/ksq-therapeutics-and-takeda-enter-broad-strategic-collaboration-to-research-develop-and-commercialize-novel-immuno-oncology-therapies/) - Collaboration includes two T-cell programs and an expansive discovery program to identify natural killer (NK) cell targets Potential for more than $100M in upfront and preclinical milestone payments, and eligible to receive additional development and commercialization milestone payments for each product KSQ retains a U.S. cost/profit-sharing option on one product, and is entitled to potential
- [KSQ® Therapeutics Appoints Qasim Rizvi, MB ChB., M.B.A., as Chief Executive Officer](https://ksqtx.com/press-releases/ksq-therapeutics-appoints-qasim-rizvi-mb-chb-m-b-a-as-chief-executive-officer/) - Dr. Rizvi brings a Proven Track Record and Commitment to Innovation, Collaboration & Team Building CAMBRIDGE, Mass., January 25, 2021 – KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced it has appointed Qasim Rizvi
- [KSQ Therapeutics Strengthens Leadership Team with Promotion of Micah Benson, Ph.D., to Senior Vice President, Head of Immunobiology and Andrew Wylie, Ph.D., to Senior Vice President, Head of Oncology](https://ksqtx.com/press-releases/ksq-therapeutics-strengthens-leadership-team-with-promotion-of-micah-benson-ph-d-to-senior-vice-president-head-of-immunobiology-and-andrew-wylie-ph-d-to-senior-vice-president-head-of-oncology/) - CAMBRIDGE, Mass., February 1, 2021- KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced key strategic management changes, promoting Micah Benson, Ph.D., to Senior Vice President and Head of Immunobiology and promoting Andrew Wylie, Ph.D.,
- [KSQ Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference](https://ksqtx.com/press-releases/ksq-therapeutics-to-present-at-the-oppenheimer-31st-annual-healthcare-conference/) - CAMBRIDGE, Mass., March 10, 2021- KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced that the company is scheduled to present at the Oppenheimer 31st Annual Healthcare Conference, to be held virtually, on Tuesday, March
- [KSQ Therapeutics Appoints Chris Heberlig as Chief Financial Officer](https://ksqtx.com/press-releases/ksq-therapeutics-appoints-chris-heberlig-as-chief-financial-officer/) - CAMBRIDGE, Mass., May 13, 2021– KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the appointment of Chris Heberlig, MBA, as Chief Financial Officer. “Chris is an seasoned biotech finance executive who brings deep experience
- [KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors](https://ksqtx.com/press-releases/ksq-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-ksq-4279-a-first-in-class-usp1-inhibitor-in-patients-with-advanced-solid-tumors/) - CAMBRIDGE, Mass., September 14, 2021- KSQ Therapeutics, a biotechnology company developing drugs to treat cancer and autoimmune diseases using its proprietary, integrated discovery platform to systematically screen the whole genome in cancer and immune cells, today announced the initiation of dosing in a Phase 1 clinical study of KSQ-4279, a first-in-class USP1 inhibitor, in patients
- [KSQ Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference](https://ksqtx.com/press-releases/ksq-therapeutics-to-present-at-the-2021-cantor-virtual-global-healthcare-conference/) - CAMBRIDGE, Mass., September 22, 2021 – KSQ Therapeutics, a biotechnology company developing drugs to treat cancer and autoimmune diseases using its proprietary, integrated discovery platform to systematically screen the whole genome in cancer and immune cells, today announced that Qasim Rizvi, Chief Executive Officer of KSQ, will present at the 2021 Cantor Virtual Global Healthcare
- [2021 SITC Poster](https://ksqtx.com/press-releases/2021-sitc-poster/)
- [SITC Poster Presentation: "Development of KSQ-001, an Engineered TIL (eTIL®) Therapy for Solid Tumors through CRISPR/Cas9-mediated Inactivation of SOCS1"](https://ksqtx.com/press-releases/sitc-poster-presentation-development-of-ksq-001-an-engineered-til-etil-therapy-for-solid-tumors-through-crispr-cas9-mediated-inactivation-of-socs1/) - Click to download PDF file.
- [KSQ Therapeutics to Participate in Upcoming Investor Conferences](https://ksqtx.com/press-releases/ksq-therapeutics-to-participate-in-upcoming-investor-conferences/) - Lexington, Mass., August 28, 2024 - KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, today announced that management will participate in the following investor conferences in September 2024: Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY) on Wednesday, September 4, 2024– Qasim Rizvi, Chief
- [KSQ Therapeutics to Present Data at the American Association for Cancer Research (AACR) 2022 Annual Meeting](https://ksqtx.com/press-releases/ksq-therapeutics-to-present-data-at-the-american-association-for-cancer-research-aacr-2022-annual-meeting/) - – Data supports ongoing Phase 1 study of KSQ-4279, a first-in-class USP1 inhibitor, in patients with advanced solid tumors CAMBRIDGE, Mass., March 22, 2022- KSQ Therapeutics (KSQ), a clinical stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, will give an oral presentation as part of
- [KSQ Therapeutics Announces Leadership and Board Additions](https://ksqtx.com/press-releases/ksq-therapeutics-announces-leadership-and-board-additions/) - Micah Benson, PhD, promoted to Chief Scientific Officer Tom Leitch joins as Chief Technology Officer Outgoing CSO Frank Stegmeier, PhD, transitions to board of directors Lexington, Mass., September 23, 2022- KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, today named Micah Benson,
- [KSQ Therapeutics Announces First Patient Dosed in Combination Portion of the Ongoing Phase 1 Study of KSQ-4279, A First-In-Class USP1 Inhibitor, In Patients with Advanced Solid Tumors](https://ksqtx.com/press-releases/ksq-therapeutics-announces-first-patient-dosed-in-combination-portion-of-the-ongoing-phase-1-study-of-ksq-4279-a-first-in-class-usp1-inhibitor-in-patients-with-advanced-solid-tumors/) - Lexington, Mass., December 7, 2022- KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, today announced the initiation of dosing in the combination therapy portion of Study KSQ-4279-1101, a Phase 1 clinical study of KSQ-4279 in patients with advanced solid tumors. This stage
- [KSQ Appoints Mahesh Karande to its Board of Directors](https://ksqtx.com/press-releases/ksq-appoints-mahesh-karande-to-its-board-of-directors/) - Lexington, Mass., December 8, 2022 – KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, today announced the appointment of Mahesh Karande, President and CEO of Omega Therapeutics, to the company’s board of directors. “Mahesh’s deep experience in company leading, product commercialization, fundraising,
- [KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics® Platform Technology](https://ksqtx.com/press-releases/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology/) - Lexington, Mass., January 25, 2023 KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics platform, announced today that Ono Pharmaceutical Co., Ltd. (“ONO”), has acquired multiple research-stage DNA damage response (DDR) programs identified using KSQ’s CRISPRomics platform technology. All the programs are novel and
- [KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL<sup>®</sup>) Therapies for the Treatment of Solid Tumors](https://ksqtx.com/press-releases/ksq-therapeutics-and-ctmc-announce-strategic-collaboration-to-accelerate-the-development-of-novel-engineered-tumor-infiltrating-lymphocyte-etil-therapies-for-the-treatment-of-solid-tumors/) - Collaboration will provide full process development and manufacturing support for KSQ’s lead eTIL programs Lexington, Mass., September 6, 2023 — KSQ Therapeutics, Inc. (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, and CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center, announced today a strategic collaboration to expedite
- [SITC Poster Presentation: “KSQ-004: Unbiased Pair-wise Discovery of SOCS1 and Regnase-1 as the Top CRISPR/Cas9 Dual-edit Combination Enhancing In vivo TIL Potency Against Solid Tumors”](https://ksqtx.com/press-releases/sitc-poster-presentation-ksq-004-unbiased-pair-wise-discovery-of-socs1-and-regnase-1-as-the-top-crispr-cas9-dual-edit-combination-enhancing-in-vivo-til-potency-against-solid-tumors/) - Click image to enlarge. Click to download PDF file.
- [KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL<sup>®</sup>) Therapy](https://ksqtx.com/press-releases/ksq-therapeutics-announces-fda-clearance-of-ind-application-for-ksq-001ex-a-crispr-cas9-engineered-tumor-infiltrating-lymphocyte-etil-therapy/) - Phase 1/2 clinical study will evaluate the safety, pharmacokinetics, and preliminary efficacy of KSQ-001EX in melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer Lexington, Mass., November 29, 2023 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University of Texas MD Anderson Cancer
- [KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL<sup>®</sup>) Therapy](https://ksqtx.com/press-releases/ksq-therapeutics-announces-first-patient-dosed-in-clinical-development-program-for-ksq-001ex-a-crispr-cas9-engineered-tumor-infiltrating-lymphocyte-etil-therapy/) - Lexington, Mass., June 12, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-001EX, a novel edited TIL therapy. KSQ-001EX consists of TIL in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing, giving it the potential
- [KSQ Therapeutics and Takeda Expand Strategic Immuno-Oncology Collaboration to Identify and Validate Novel Tumor Targets](https://ksqtx.com/press-releases/ksq-therapeutics-and-takeda-expand-strategic-immuno-oncology-collaboration-to-identify-and-validate-novel-tumor-targets/) - Expanded collaboration focused on novel target discovery and validation to inform the development of targeted therapies that address resistance mechanisms in patients with cancer Agreement expands the companies’ successful ongoing collaboration focused on discovering natural killer (NK) and T-cell targets Lexington, Mass., May 17, 2023 KSQ Therapeutics, (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using
- [KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer](https://ksqtx.com/press-releases/ksq-therapeutics-enters-worldwide-license-agreement-with-roche-for-ksq-4279-a-clinical-stage-usp1-inhibitor-for-cancer/) - Lexington, Mass., July 13, 2023 — KSQ Therapeutics, Inc. (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced today it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279. KSQ-4279 is a first-in-class, potent, and selective small molecule inhibitor of USP1, a

## Leadership

- [Anna Truppel-Hartmann](https://ksqtx.com/leadership/anna-truppel-hartmann/) - Anna Truppel-Hartmann is a seasoned medical professional with over 15 years of experience in the pharmaceutical and biotechnology sectors. She earned her medical degree in Switzerland and brings a wealth of expertise and accomplished track record in clinical development, medical affairs, patient engagement, and talent development. She has held key leadership roles at both large
- [Patty Harris](https://ksqtx.com/leadership/patty-harris/) - Patty Harris has over 20 years of global clinical development experience across a variety of oncology/hematology indications. Prior to joining KSQ, Patty was Vice President of Clinical Sciences at Cogent Biosciences and at Unum Therapeutics where she led the clinical development for small molecule and modified autologous cellular therapies. She has worked at both emerging
- [Elizabeth Twomey-Gansler](https://ksqtx.com/leadership/elizabeth-twomey-gansler/) - Elizabeth Twomey-Gansler has served as the Head of Human Resources at KSQ Therapeutics since April 2019. Prior to joining KSQ, Elizabeth worked in executive search focusing on the recruitment of physicians and clinical development professionals for life-science companies of all sizes at The Higgins Group. Elizabeth has received her Bachelor of Social Work from Saint
- [Thomas Leitch](https://ksqtx.com/leadership/thomas-leitch/) - Tom brings nearly 25 years of leadership experience in cell & gene therapy, biologics, and vaccines to his role as Chief Technology Officer. His experiences span Manufacturing Sciences, CMC Strategy Development, Internal and External Manufacturing Operations, Quality, Engineering, Tech Transfer, and Supply Chain across a broad range of leading biopharmaceutical companies. Tom came to KSQ
- [Micah Benson](https://ksqtx.com/leadership/micah-benson/) - Micah Benson joined KSQ at its founding and was responsible for building KSQ’s Immuno-Oncology and Autoimmunity efforts, leading to a clinical-stage portfolio of multiple first-in-class therapeutics. A co-inventor of KSQ’s foundational Immune CRISPRomics® platform, Micah's work led to the discovery of SOCS1 and Regnase-1 and the development of KSQ’s eTIL® programs, including KSQ-001EX and KSQ-004EX,
- [Lance Ostrom](https://ksqtx.com/leadership/lance-ostrom/) - Lance brings over 20 years industry experience and over the past ten years has focused his work in business development at large pharmaceutical companies and small biotechs. At KSQ he’s led three major transactions with Ono, Takeda and Roche resulting in significant runway extension and partners poised to leverage KSQ discoveries. Before joining KSQ, Lance
- [Chris Heberlig](https://ksqtx.com/leadership/chris-heberlig/) - Chris Heberlig has more than two decades of financial, strategic and operational experience in the biotechnology industry with a background supporting companies advancing from private to public markets and from early-stage development towards commercialization. Prior to KSQ, Chris served as Executive Vice President, Chief Financial Officer at Kiniksa Pharmaceuticals, where he was part of the
- [Qasim Rizvi](https://ksqtx.com/leadership/qasim-rizvi/) - Qasim Rizvi is a trained surgeon and highly accomplished health care executive with broad experience in the biopharmaceuticals industry. He has a distinguished track record of innovation and operational excellence, coupled with a strong commitment to collaboration and teambuilding. Prior to joining KSQ, Dr. Rizvi was senior vice president of operations & chief commercial officer

## Board of Directors

- [David Darst](https://ksqtx.com/board-of-directors/david-darst/) - David Darst is a Growth Partner with Flagship Pioneering. David is a board member and co-responsible partner for multiple growth stage portfolio companies. He supports their organizational development, long-term strategy, financing, and business development efforts to generate the greatest value creation and impact for those companies. Prior to joining Flagship, David was the COO/ CFO
- [Richard Moscicki, MD](https://ksqtx.com/board-of-directors/richard-moscicki-md/) - Richard Moscicki has more than 25 years of leadership experience in translational medicine, clinical development, regulatory affairs and medical affairs in the pharmaceutical industry. His experience includes serving as the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER). Rich has also served
- [Kristen Hege, MD](https://ksqtx.com/board-of-directors/kristen-hege-md/) - Dr. Hege retired from Bristol Myers Squibb and UCSF in March of 2023 to pursue her lifelong dream of thru hiking the 2650-mile Pacific Crest Trail. In her BMS role as SVP Early Clinical Development, Hematology, Oncology & Cell Therapy, she was responsible for advancing a pipeline of small molecules, biologics and cell therapies from
- [John Lepore, MD](https://ksqtx.com/board-of-directors/john-lepore-md/) - John Lepore, M.D. is CEO-Partner at Flagship Pioneering and CEO of ProFound Therapeutics, an early stage biotechnology company harnessing the expanded human proteome to identify novel, first-in-class protein drugs and drug targets. Dr. Lepore joined ProFound after 17 years at GSK where he had extensive experience leading international R&D organizations across diverse therapeutic areas. He
- [Doug Cole](https://ksqtx.com/board-of-directors/doug-cole/) - Doug Cole joined Flagship Pioneering in 2001. He focuses on life science. At Flagship, Doug has co-founded Ensemble Therapeutics, Foghorn Therapeutics (NASDAQ: FHTX), Inzen Therapeutics, Moderna (NASDAQ: MRNA), Permeon Biologics, Sigilon Therapeutics, (NASDAQ: SGTX), and Syros Pharmaceuticals (NASDAQ: SYRS). He has led investments in Agios Pharmaceuticals (NASDAQ: AGIO), Alvine Pharmaceuticals, Avedro (NASDAQ: AVDR, acquired by Glaukos), CombinatoRx (NASDAQ: ZLCS), Concert Pharmaceuticals (NASDAQ: CNCE), Denali Therapeutics (NASDAQ: DNLI), Editas (NASDAQ: EDIT), Quanterix Corporation
- [Frank Stegmeier, PhD](https://ksqtx.com/board-of-directors/frank-stegmeier-phd/) - Frank Stegmeier is an industry-leading expert in genetics, cancer biology and functional genomics who has led the industrialized application of functional genomics for oncology drug discovery in the pharmaceutical industry. Prior to joining KSQ Therapeutics, Frank served as Director and Head of Global Oncology Target Discovery at the Novartis Institutes for Biomedical Research (NIBR), where
- [Ravi Mehrotra, PhD](https://ksqtx.com/board-of-directors/ravi-mehrotra-phd/) - Ravi Mehrotra joined Flagship Pioneering in 2023. He works with Flagship Growth companies to help maximize value creation opportunities for their bioplatforms. Prior to joining Flagship, Ravi spent 20+ years in biotechnology equity research and investment banking and he has held various executive team operational roles. He was previously Senior Managing Director on Evercore ISI’s
- [Mahesh Karande](https://ksqtx.com/board-of-directors/mahesh-karande/) - Mahesh is the President and CEO of Omega Therapeutics (Nasdaq: OMGA), a clinical-stage biotechnology company pioneering a new field of epigenomic programming to use mRNA therapeutics as programmable epigenetic medicines. At Omega, he has led the translation of completely new science into a drug development and therapeutic platform with a broad pipeline in oncology, regenerative
- [Alan Crane, MBA](https://ksqtx.com/board-of-directors/alan-crane-mba/) - Alan Crane is a Partner and Entrepreneur at Polaris Partners focusing on building and investing in healthcare companies. He has served as founder and/or has played a significant role as chairman and CEO in building six Polaris companies including: Momenta Pharmaceuticals (NASDAQ: MNTA), Cerulean Pharma (NASDAQ:CERU), Visterra, Navitor Pharmaceuticals, XTuit Pharmaceuticals and Arsia Therapeutics. In
- [Qasim Rizvi, MB.ChB.](https://ksqtx.com/board-of-directors/qasim-rizvi-mb-chb/) - Qasim Rizvi is a trained surgeon and highly accomplished health care executive with broad experience in the biopharmaceuticals industry. He has a distinguished track record of innovation and operational excellence, coupled with a strong commitment to collaboration and teambuilding. Prior to joining KSQ, Dr. Rizvi was senior vice president of operations & chief commercial officer

## Scientific Advisors

- [Michael T. Lotze, MD, FACS](https://ksqtx.com/scientific-advisors/michael-t-lotze-md-facs/) - Michael T. Lotze, MD, FACS is Professor of Surgery, Immunology, and Bioengineering; Director of the DAMP Laboratories at the UPMC Hillman Cancer Center within the University of Pittsburgh Medical Center Hillman Cancer Center. He is a long-time SITC enthusiast, attending his first meeting in Williamsburg in 1989, presiding over the Society in 1998, and launching
- [Jason Bock, PhD](https://ksqtx.com/scientific-advisors/jason-bock-phd/) - Jason Bock, PhD, is a biotech leader with a track record of building organizations that translate cutting-edge science into impactful biologic therapies. In 2019, he joined MD Anderson to establish the Biologics Development group, an internal biotech initiative focused on advancing MDACC-invented biologics. Under his leadership, the group spun off into CTMC in May 2022—a
- [Shari Pilon-Thomas, PhD](https://ksqtx.com/scientific-advisors/shari-pilon-thomas-phd/) - Shari Pilon-Thomas PhD is a Senior Member of the Immunology Department and Co-Director of the Center for Immunization and Infection Research in Cancer (CIIRC) at Moffitt Cancer Center. She currently serves as the Co-Chair of the SITC Cell Therapy Committee. She received her PhD in Immunology/Microbiology from Wayne State University and completed her Postdoctoral Fellow
- [Chantale Bernatchez, PhD](https://ksqtx.com/scientific-advisors/chantale-bernatchez-phd/) - Chantale Bernatchez, Ph.D., is Head of Process Development at CTMC. With more than 20 years of experience in the fields of immunology and T-cell therapy, Dr. Bernatchez has been instrumental in advancing academic and biotechnology work in TIL (tumor-infiltrating lymphocytes) and CAR-T (chimeric antigen receptor T-cells) biology, process development, and manufacturing. Dr. Bernatchez leads CTMC's
- [Michal Besser, PhD](https://ksqtx.com/scientific-advisors/michal-besser-phd/) - Michal Besser, PhD, is a global expert in immunology, cell therapy, and translational medicine, boasting an 18-year career spanning both academia and industry. Michal serves as Chief Technology Officer at the Davidoff Comprehensive Cancer Center, Rabin Medical Center, and as an Assistant Professor at the Department of Clinical Immunology and Microbiology at Tel-Aviv University, Israel.

## Investors

- [LG](https://ksqtx.com/investors/lg/)
- [TD Cowen](https://ksqtx.com/investors/td-cowen/)
- [Alexandria](https://ksqtx.com/investors/alexandria/)
- [Alpha Wave Global](https://ksqtx.com/investors/alpha-wave-global/)
- [Lilly Asia Ventures](https://ksqtx.com/investors/lilly-asia-ventures/)
- [Invus](https://ksqtx.com/investors/invus/)
- [Baillie Gifford](https://ksqtx.com/investors/baillie-gifford/)
- [Polaris Partners](https://ksqtx.com/investors/polaris-partners/)
- [ARCH Venture](https://ksqtx.com/investors/arch-venture/)
- [Flagship Pioneering](https://ksqtx.com/investors/flagship-pioneering/)

## Categories

- [Uncategorized](https://ksqtx.com/category/uncategorized/)